Description
Genferon Pharmacodynamics
GENFERON® is a combined preparation, the action of which is caused by its constituent components. It has topical and systemic effects.
Recombinant human interferon alfa-2b, produced by Escherichia coli strain, into which, by genetic engineering methods, human interferon alfa-2b gene was introduced, is the part of GENFERON® preparation.
Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. Antiviral effect is mediated by activation of a number of intracellular enzymes that inhibit viral replication. Immunomodulatory effect is primarily manifested by strengthening the cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. This is achieved by activation of CD8+ T-rollers, NK-cells (natural killer cells), increasing differentiation of B-lymphocytes and their production of antibodies, activation of monocytic-macrophage system and phagocytosis as well as increasing expression of molecules of the main histocompatibility complex of type I, which increases the possibility of recognition of infected cells by the cells of immune system. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane provides their active participation in liquidation of pathological foci; besides, due to the influence of interferon, restoration of production of secretory immunoglobulin A is achieved. Antimicrobial effect is mediated by immune system reactions enhanced under the influence of interferon.
Taurine promotes normalization of metabolic processes and tissue regeneration, has membranostabilizing and immunomodulatory effects. As a strong antioxidant, taurine directly interacts with reactive oxygen species, the excessive accumulation of which contributes to pathological processes. Taurine helps to preserve the biological activity of interferon, increasing the therapeutic effect of the drug. Benzocaine (anesthesin) is a local anesthetic. It reduces the permeability of the cell membrane for sodium ions, displaces calcium ions from the receptors located on the inner surface of the membrane, blocks the conduction of nerve impulses. Prevents the occurrence of pain impulses in the endings of sensitive nerves and their conduction along the nerve fibers. It has only local effect without being absorbed into the systemic bloodstream.
Indications
As part of the complex treatment of infectious-inflammatory diseases of the urogenital tract in adults: Genital herpes, chlamydia, ureaplasmosis, mycoplasmosis, recurrent vaginal candidiasis, gardnerellosis, trichomonosis, papillomavirus infection, bacterial vaginosis, cervical erosion, cervicitis, vulvovaginitis, bartholinitis, adnexitis, prostatitis, urethritis, balanitis, balanopostitis.
In the treatment of acute bronchitis in adults.
In the treatment of chronic recurrent cystitis of bacterial etiology in adults.
In the treatment of chronic endometritis in adults.
Contraindications .
Individual intolerance to interferon and other ingredients of the drug.
Dosage and administration method
- Infectious-inflammatory diseases of the urogenital tract in women.
1 suppository (250 000 ME or 500 000 ME or 1 000 000 ME, depending on the disease severity) vaginally or rectally (depending on the disease character) 2 times a day for 10 days. In prolonged forms, 1 suppository 3 times a week every other day for 1-3 months. - In cases of severe vaginal infection and inflammation, 1 suppository 500 000 IU intravaginally in the morning and 1 suppository 1 000 000 IU rectally at night in combination with a vaginal suppository containing antimicrobial/fungicidal agents is possible. For the normalization of local immunity during treatment of infectious-inflammatory diseases of urogenital tract in women with gestational age of 13-40 weeks, 1 suppository with 250 000 IU vaginally 2 times daily during 10 days is used.
- Infectious-inflammatory diseases of the urogenital tract in men.
- Rectally 1 suppository (500 000 ME or 1 000 000 ME depending on the disease severity) 2 times a day for 10 days.
3. As part of the complex therapy of acute bronchitis in adults.
1 suppository (1 000 000 ME) rectally 2 times a day for 5 days.
4. As part of the complex therapy of chronic recurrent cystitis in adults. - During acute condition – 1 suppository (1 000 000 ME) rectally 2 times a day for 10 days in combination with the standard course of antibacterial therapy, further 1 suppository (1 000 000 ME) rectally every other day for 40 days as prevention of relapses.
5. As part of the complex therapy of chronic endometritis in adults. Rectally 1 suppository (1 000 000 IU) 2 times a day for 10 days, then 1 suppository (500 000 IU) rectally 2 times a day for 10 days, then rectally 1 suppository (1 000 000 IU) every other day for 10 days.
